Cambridge, UK-based Healx, which aims to use AI to help discover new treatments for rare diseases, raises $56M Series B led by Atomico
Context & Ripple Effects
Healx's raise lands eighteen months after BenevolentAI's $115M round at a $2.1B valuation, which established London as a credible home for AI-driven drug discovery and gave later UK entrants a benchmark to raise against. Healx takes a narrower slice of that thesis — rare diseases, where small patient populations have historically left treatments economically unattractive to conventional pharma R&D.
First-order effects
- Atomico now leads three UK health-AI rounds in under a year, following its Series A in medical-messaging startup Accurx and Kheiron Medical Technologies' cancer-detection raise — Healx extends the firm from diagnostics and care coordination into therapeutics discovery.
Second-order effects
- The $56M Series B pressures other AI drug-discovery startups to show pipeline traction rather than platform promises, since investors can now compare Healx against BenevolentAI's much larger war chest within the same national ecosystem.
Third-order effects
- If rare-disease programs keep attracting dedicated capital, Europe's AI-health funding clusters around vertically specialized discovery shops rather than generalist platforms — with Cambridge joining London as a recognized node alongside the BenevolentAI anchor.
The trend: European VCs are serially backing applied-AI healthcare startups, and Atomico's string of UK health-tech leads shows the thesis moving from tools and diagnostics into drug discovery itself.